Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono JS, Kaye SB, Molife LR, Banerji U.
Basu B, et al. Among authors: puglisi m.
Oncology. 2012;83(4):177-82. doi: 10.1159/000341152. Epub 2012 Aug 7.
Oncology. 2012.
PMID: 22889980
Free PMC article.
Clinical Trial.